Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 4/20 | 0.41 |
| ▸ | PLAU | P00749 | 4/20 | 0.41 |
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PLAT | P00750 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448396 | 0.90 | KDM4E (0.41) | PLGPLAUF10F2PLAT | |
| SCHEMBL6449844 | 0.85 | PLG (0.44) | PLGPLAUF10F2PLAT | |
| SCHEMBL6454710 | 0.84 | PLG (0.43) | PLGPLAUF10F2PLAT | |
| SCHEMBL6450094 | 0.83 | TRPA1 (0.41) | PLGPLAUF10F2PLAT | |
| SCHEMBL6452888 | 0.82 | PLG (0.48) | PLGPLAUF10F2PLAT | |
| SCHEMBL6454173 | 0.79 | S1PR1 (0.47) | PLGPLAUF10F2PLAT | |
| SCHEMBL6450021 | 0.79 | ADORA2A (0.53) | PDE5AKDRTRPV1HSD17B10 | |
| SCHEMBL6448775 | 0.78 | SMN1; SMN2 (0.53) | PLGPLAUF10F2PLAT | |
| SCHEMBL6448407 | 0.78 | HPGD (0.43) | PLGPLAUF10F2PLAT | |
| SCHEMBL6454404 | 0.76 | KDR (0.39) | KDRTRPV1GAAMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | PLG 4331/4885PLAU 3775/4885F10 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.